These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9595916)

  • 21. Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings.
    Ingle JN
    Clin Cancer Res; 2005 Jan; 11(2 Pt 2):900s-5s. PubMed ID: 15701884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
    Mauri D; Pavlidis N; Polyzos NP; Ioannidis JP
    J Natl Cancer Inst; 2006 Sep; 98(18):1285-91. PubMed ID: 16985247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen.
    Buzdar AU
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):623-9. PubMed ID: 12503208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aromatase inhibitors in breast cancer therapy.
    Brueggemeier RW
    Expert Rev Anticancer Ther; 2002 Apr; 2(2):181-91. PubMed ID: 12113240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aromatase inhibitors in metastatic breast cancer.
    Buzdar AU; Plourde PV; Hortobagyi GN
    Semin Oncol; 1996 Aug; 23(4 Suppl 9):28-32. PubMed ID: 8824462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
    Hamilton A; Piccart M
    Ann Oncol; 1999 Apr; 10(4):377-84. PubMed ID: 10370778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of aromatase as treatment of breast carcinoma in postmenopausal women.
    Santen RJ; Boucher AE; Santner SJ; Henderson IC; Harvey H; Lipton A
    J Lab Clin Med; 1987 Mar; 109(3):278-89. PubMed ID: 3546561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer.
    Johnston SR; Smith IE; Doody D; Jacobs S; Robertshaw H; Dowsett M
    Cancer Res; 1994 Nov; 54(22):5875-81. PubMed ID: 7954417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiestrogen treatment of breast cancer: an overview.
    Pearson OH; Manni A; Arafah BM
    Cancer Res; 1982 Aug; 42(8 Suppl):3424s-3429s. PubMed ID: 7044524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aromatase inhibition and antiestrogen therapy in early breast cancer treatment and chemoprevention.
    Ingle JN
    Oncology (Williston Park); 2001 May; 15(5 Suppl 7):28-34. PubMed ID: 11396362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aromatase inhibitors in the treatment of postmenopausal breast cancer.
    Bajetta E; Zilembo N; Bichisao E
    Drugs Aging; 1999 Oct; 15(4):271-83. PubMed ID: 10582774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer.
    Michaud LB; Buzdar AU
    Drug Saf; 1999 Oct; 21(4):297-309. PubMed ID: 10514021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors.
    Goss PE; Strasser K
    Drugs; 2002; 62(6):957-66. PubMed ID: 11929341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma.
    Smith IE; Harris AL; Morgan M; Gazet JC; McKinna JA
    Cancer Res; 1982 Aug; 42(8 Suppl):3430s-3433s. PubMed ID: 7044525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer.
    Harvey HA; Lipton A; White DS; Santen RJ; Boucher AE; Shafik AS; Dixon RJ
    Cancer Res; 1982 Aug; 42(8 Suppl):3451s-3453s. PubMed ID: 6177405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aromatase inhibitors and their use in the adjuvant setting.
    Coombes RC
    Recent Results Cancer Res; 1998; 152():277-84. PubMed ID: 9928565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate.
    Lønning PE; Geisler J; Johannessen DC; Ekse D
    J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):255-60. PubMed ID: 9365198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of letrozole in the treatment of advanced breast cancer.
    Karnon J
    Expert Rev Pharmacoecon Outcomes Res; 2004 Aug; 4(4):383-91. PubMed ID: 19807297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aromatase inhibitors as adjuvant therapies in patients with breast cancer.
    Coombes RC; Gibson L; Hall E; Emson M; Bliss J
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):309-11. PubMed ID: 14623526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overview of recent development of aromatase inhibitors.
    Brodie AM
    Cancer Res; 1982 Aug; 42(8 Suppl):3312s-3314s. PubMed ID: 7083192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.